Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UNITED THERAPEUTICS (UTHR) EBIT: 2009-2025

Historic EBIT for UNITED THERAPEUTICS (UTHR) over the last 17 years, with Sep 2025 value amounting to $388.5 million.

  • UNITED THERAPEUTICS's EBIT rose 13.23% to $388.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 16.73%. This contributed to the annual value of $1.4 billion for FY2024, which is 16.21% up from last year.
  • UNITED THERAPEUTICS's EBIT amounted to $388.5 million in Q3 2025, which was up 6.58% from $364.5 million recorded in Q2 2025.
  • UNITED THERAPEUTICS's EBIT's 5-year high stood at $388.5 million during Q3 2025, with a 5-year trough of -$64.8 million in Q1 2021.
  • For the 3-year period, UNITED THERAPEUTICS's EBIT averaged around $336.2 million, with its median value being $343.1 million (2024).
  • Per our database at Business Quant, UNITED THERAPEUTICS's EBIT plummeted by 138.87% in 2021 and then spiked by 544.44% in 2022.
  • Quarterly analysis of 5 years shows UNITED THERAPEUTICS's EBIT stood at $169.8 million in 2021, then grew by 3.42% to $175.6 million in 2022, then skyrocketed by 48.12% to $260.1 million in 2023, then spiked by 37.52% to $357.7 million in 2024, then climbed by 13.23% to $388.5 million in 2025.
  • Its last three reported values are $388.5 million in Q3 2025, $364.5 million for Q2 2025, and $382.8 million during Q1 2025.